International / English

Merck Millipore is now Merck

The Drug Candidate Journey: Manufacturing

The Finished Product

Whether manufacturing clinical trial batches or commercial production, your manufacturing process must meet the same high standards as your R&D and clinical trials.

Things to consider in the manufacturing phase:

  • Regulatory compliance
  • Engineering optimization
  • Single use manufacturing
  • Your own 12K to 20K bioreactor or a CMO?

Talk with us to learn more about your options – and opportunities for manufacturing excellence.

Additional Resources

U.S.: For assistance with Food and Drug Administration, including INDs; and information on clinical trials

  • Funding

    Primary Need

    Lack of funding is one of the main reasons for failure of a biologic.

    Estimates vary, but some project it costs $8-10 million just to get to IND stage, another $8-10 million for Phase I, and $20-40 million for Phase II, depending on design. Phase III costs considerably more.

    Don’t let a good drug go to waste, or too much of its value to third parties, because of funding issues. There are ways to fund biotech, from biotech crowdfunding, nondilutive funding, and nonsoursive funding, to biotech grants, angel investors, venture capital and other resources.

    More >
  • Intellectual Property

    Intellectual property strategy is essential to protecting ideas and the business. Emerging biotech community members shared their insights.

    More >
  • Regulatory Guidance

    Stay the Course

    On the journey to commercialization, be sure to stay the course by understanding the global pharmaceutical regulatory landscape.

    We offer

    More >

Emerging Biotech: Stay Current

Emerging Biotech Upstream Forum
Speed to clinic: direct route from cell line to bioreactor

Join us and your peers for the Emerging Biotech Upstream Forum to discuss latest trends, innovations, and technologies to help you speed up your molecule to clinic: from cell line development to bioreactor scale-up.

Tuesday, November 14, 2017
San Francisco, CA
Hilton Garden Inn, San Francisco Airport North,
670 Gateway Boulevard

Thursday, November 16, 2017
San Diego, CA
DoubleTree Del Mar, 11915 El Camino Real


Refresh Startup Battle Winner Announced at Labiotech in Berlin

Merck recently sponsored a program recognizing emerging biotech companies. The Refresh Startup Battle is a unique occasion for Biotech Startups to show the world their awesome ideas as they pitch in front of the best audience European biotech has to offer. Learn more about the contestants and the winner of the Startup Battle.

Find out more about our programs:
Grants | Events | Innovation | Agreements

Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.

More details about EB Programs>

UPCOMING WEBINAR: Venture Capital Funding: An Insider’s View

Learn more about the ABCs of venture capital including how it works and the role of a corporate venture capital.

Register Now >

WEBINAR: Accelerated ADC Development with Integrated Supply Chain Solutions

Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.

Watch Now >

WEBINAR: RNA Based Therapeutics and Vaccines: Bioprocessing Technology Trends

Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.

Watch this Webinar >

WEBINAR: Managing Process Scale-up and Tech Transfer

Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.

Watch this Webinar >

Webinars On-Demand >

WHITE PAPER: 2017 Life Science Executive Summit

Establishing an open dialog within the biotech community....

Read more and download >

The Changing Biopharma Risk Equation

A report from the The Economist Intelligence Unit sponsored by Merck.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.

Read the study >

Contact Us

Research. Development. Production.

We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.

© 2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
Merck Millipore is a part of Merck.